These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10607253)

  • 21. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis.
    Magrin S; Craxì A; Fabiano C; Fiorentino G; Marino L; Almasio P; Pinzello GB; Palazzo U; Vitale M; Maggio A
    J Med Virol; 1992 Nov; 38(3):200-6. PubMed ID: 1283753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presence of HCV RNA in peripheral blood mononuclear cells may predict patients response to interferon and ribavirin therapy.
    Zaman N; Asad MJ; Raza A; Raja GK; Akhter S; Mahmood M; Mahmood RT
    Ann Saudi Med; 2014; 34(5):401-6. PubMed ID: 25827697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy.
    Picciotto A; Campo N; Brizzolara R; Sinelli N; Poggi G; Grasso S; Celle G
    Eur J Gastroenterol Hepatol; 1997 Jan; 9(1):67-9. PubMed ID: 9031902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study.
    Flichman D; Colombatto P; Randone A; Baldi M; Bellati G; Negro F; Oliveri F; Colucci G; Verme G; Bonino F; Brunetto MR
    Clin Diagn Virol; 1997 May; 8(1):63-70. PubMed ID: 9248659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow up of sustained viral response after treatment of hepatitis C with pegylated interferon alpha-2a in hemodialysis patients.
    Dzekova P; Asani A; Selim G; Gelev S; Trajceska L; Amitov V; Selja N; Zabzun M; Mena S; Gaseva M; Sikole A
    Int J Artif Organs; 2009 Mar; 32(3):180-4. PubMed ID: 19440994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
    Chemello L; Cavalletto L; Casarin C; Bonetti P; Bernardinello E; Pontisso P; Donada C; Belussi F; Martinelli S; Alberti A
    Ann Intern Med; 1996 Jun; 124(12):1058-60. PubMed ID: 8633819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.
    Kasahara A; Hayashi N; Mochizuki K; Hiramatsu N; Sasaki Y; Kakumu S; Kiyosawa K; Okita K
    J Viral Hepat; 2000 Sep; 7(5):343-51. PubMed ID: 10971822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
    Aiyama T; Yoshioka K; Hirofuji H; Kusakabe A; Yamada M; Tanaka K; Kakumu S
    Dig Dis Sci; 1994 Oct; 39(10):2244-9. PubMed ID: 7924750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of pretreatment viral load and monitoring of serum hepatitis C virus RNA in predicting responses to interferon-alpha2a treatment of chronic hepatitis C. Hanshin Chronic Hepatitis C Study Group.
    Wada M; Kang KB; Nishigami T; Shimoyama T
    J Interferon Cytokine Res; 1997 Nov; 17(11):707-12. PubMed ID: 9402109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of persistence of IFN-alpha treatment response in chronic hepatitis C patients according with HCV-RNA presence in PBMC].
    Piekarska A; Sidorkiewicz M; Lewandowska U; Kuydowicz J
    Pol Arch Med Wewn; 2001 Oct; 106(4):939-44. PubMed ID: 11993413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.
    Brouwer JT; Hansen BE; Niesters HG; Schalm SW
    J Hepatol; 1999 Feb; 30(2):192-8. PubMed ID: 10068095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.
    Di Marco V; Almasio P; Vaccaro A; Ferraro D; Parisi P; Cataldo MG; Di Stefano R; Craxì A
    J Hepatol; 2000 Sep; 33(3):456-62. PubMed ID: 11020002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained response to interferon-alpha2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C. The Donor Surveillance Study Group.
    Prati D; Zanella A; Zanuso F; Vianello L; Della Torre E; Mozzi F; Carriero PL; Zahm F; Donato MF; Colombo M; Sirchia G
    J Viral Hepat; 2000 Sep; 7(5):352-60. PubMed ID: 10971823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.